Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.

Ibrexafungerp: Activity against Pneumocystis

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
September 2018

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

Combination Therapy with SCY-078 and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

V. Petraitis, S. Barat, K. Borroto-Esoda, D. Angulo, T. Walsh
AAA 2018
February 2018

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis

K. Borroto-Esoda, S. Barat, D. Angulo, C. Carruthers, K. Holden, P. Warn
IDWeek 2017
October 2017

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates

S. Barat, D. Angulo, K. Borroto-Esoda, M. Ghannoum
IDWeek 2017
October 2017